Clinical Trials Logo

Clinical Trial Summary

Heart failure with preserved ejection fraction has a high mortality, which is contrasted by a total absence of therapy options besides symptomatic diuretic treatment. This study aims to explore the potential of renal denervation as a treatment option for heart failure with preserved ejection fraction.


Clinical Trial Description

Heart failure is one of the most important diseases worldwide, with a 5-year mortality of up to 75% in symptomatic patients. While substantial progress has been made in the treatment of patients with reduced left ventricular ejection fraction (HFrEF), mortality for patients with heart failure and preserved ejection fraction (HFpEF) remains unchanged, despite a comparable prevalence and mortality of the disease as for heart failure with reduced ejection fraction. HFpEF is a heterogeneous condition and has been a diagnostic and therapeutic challenge for clinicians and researchers over the past decades. While some rare cases of HFpEF can be attributed to specific diseases like amyloidosis, in most other patients common characteristics are increased ventricular filling pressures and ventricular and arterial stiffening as frequently caused by ageing, diabetes and arterial hypertension. Furthermore, increased sympathetic activity has been described as one pathogenic contributor to chronic heart failure and is associated with poor clinical prognosis. It also leads to a more pulsatile BP profile which can cause a mismatch in arterio-ventricular coupling. The modulating effects on the sympathetic nervous system induced by renal denervation (RDN) should be beneficial in HFpEF, as they improve resting and exercise hemodynamics due to an improved ventriculoarterial coupling by reduced aortic stiffness and lower systemic blood pressure. In addition, RDN leads to optimized stroke volume and stroke work and might affect cardiac preload by improving blood distribution into the splanchnic compartment. This study aims to explore the potential of RDN as a therapy for HFpEF in a single center pilot trial using a randomized, sham-controlled double-blind design. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05030987
Study type Interventional
Source University of Leipzig
Contact Philipp Lurz, Prof. Dr.
Phone 49 341
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date September 30, 2021
Completion date March 31, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04153136 - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study) Phase 2
Not yet recruiting NCT04913805 - Matching Perfusion and Metabolic Activity in HFpEF Phase 2
Recruiting NCT04535726 - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting NCT04594499 - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Recruiting NCT03550235 - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Recruiting NCT04633460 - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure Phase 2
Not yet recruiting NCT05002075 - Efficacy of an m-Health Cardiac Rehabilitation Program in Heart Failure With Preserved Ejection Fraction N/A
Completed NCT01726049 - Sildenafil in HFpEF and PH Phase 3
Completed NCT01185067 - Physiological Effects of Grape Seed Extract in Diastolic Heart Failure Phase 1
Completed NCT01091467 - Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction
Not yet recruiting NCT04945707 - Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF) Phase 4
Recruiting NCT04237701 - Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System
Completed NCT03254485 - A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Phase 2
Recruiting NCT02901184 - Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction Phase 3
Completed NCT01618981 - LEft Atrial Pacing in Diastolic Heart Failure N/A
Recruiting NCT04886713 - Adipose Tissue Inflammation in HFpEF
Active, not recruiting NCT04019613 - Assessment of Pulmonary Congestion During Cardiac Hemodynamic Stress Testing N/A
Recruiting NCT04727073 - Spironolactone In The Treatment of Heart Failure Phase 3
Completed NCT03837470 - Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction Early Phase 1
Completed NCT04163861 - Frequency and Magnitude of Subclinical Systolic Dysfunction by Strain Imaging in Heart Failure With Preserved Ejection Fraction